PURPOSE: CCR6 is expressed in various tumors and has been implicated in the process of tumor progression and metastasis. Its chemokine ligand, CCL20, is present in different tissues including lymph nodes, but also the normal prostate. This study was performed to investigate a potential relationship between CCR6 and CCL20 expression and features of human prostate cancer (PCA) at time of primary treatment. METHODS: Immunohistochemistry was used to detect CCR6 and CCL20 expression in archival tissue blocks of 80 PCA cases of various tumor grades and stages. Evaluation was semiquantitatively by visual scoring and quantitatively by digital image analysis (DIA). CCR6 and CCL20 expression was compared with Gleason score, stage, perineural invasion, nodal metastasis, age, and preoperative serum prostate-specific antigen (PSA) level by univariate and multivariate analyses. RESULTS: Staining intensity of CCR6 in tumor cells varied considerably, with it being: weak in 21 tumors (26.2%), intermediate in 44 (55.0%), and strong in 15 (18.8%), with 3.6-log differences in DIA measurements. CCL20 expression was absent in eight tumors (10.0%), weak in 41 (51.2%), intermediate in 23 (28.8%), and strong in eight (10.0%). CCR6 and CCL20 expression did not correlate. CCR6 expression was associated with T-category (P < 0.0005), Gleason score (P = 0.003), and lymph node metastasis (P = 0.002). CONCLUSIONS: Expression levels of CCR6 in PCA were associated with clinical and pathologic features of more advanced and aggressive prostate cancer. Thus, CCR6 may directly or indirectly be involved in tumor progression and should be evaluated as novel candidate target molecule for specific treatment interventions.
PURPOSE:CCR6 is expressed in various tumors and has been implicated in the process of tumor progression and metastasis. Its chemokine ligand, CCL20, is present in different tissues including lymph nodes, but also the normal prostate. This study was performed to investigate a potential relationship between CCR6 and CCL20 expression and features of humanprostate cancer (PCA) at time of primary treatment. METHODS: Immunohistochemistry was used to detect CCR6 and CCL20 expression in archival tissue blocks of 80 PCA cases of various tumor grades and stages. Evaluation was semiquantitatively by visual scoring and quantitatively by digital image analysis (DIA). CCR6 and CCL20 expression was compared with Gleason score, stage, perineural invasion, nodal metastasis, age, and preoperative serum prostate-specific antigen (PSA) level by univariate and multivariate analyses. RESULTS: Staining intensity of CCR6 in tumor cells varied considerably, with it being: weak in 21 tumors (26.2%), intermediate in 44 (55.0%), and strong in 15 (18.8%), with 3.6-log differences in DIA measurements. CCL20 expression was absent in eight tumors (10.0%), weak in 41 (51.2%), intermediate in 23 (28.8%), and strong in eight (10.0%). CCR6 and CCL20 expression did not correlate. CCR6 expression was associated with T-category (P < 0.0005), Gleason score (P = 0.003), and lymph node metastasis (P = 0.002). CONCLUSIONS: Expression levels of CCR6 in PCA were associated with clinical and pathologic features of more advanced and aggressive prostate cancer. Thus, CCR6 may directly or indirectly be involved in tumor progression and should be evaluated as novel candidate target molecule for specific treatment interventions.
Authors: J Kleeff; T Kusama; D L Rossi; T Ishiwata; H Maruyama; H Friess; M W Büchler; A Zlotnik; M Korc Journal: Int J Cancer Date: 1999-05-17 Impact factor: 7.396
Authors: R Hromas; P W Gray; D Chantry; R Godiska; M Krathwohl; K Fife; G I Bell; J Takeda; S Aronica; M Gordon; S Cooper; H E Broxmeyer; M J Klemsz Journal: Blood Date: 1997-05-01 Impact factor: 22.113
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: Carl C Schimanski; Stefan Schwald; Nektaria Simiantonaki; Caren Jayasinghe; Ursula Gönner; Vanessa Wilsberg; Theodor Junginger; Martin R Berger; Peter R Galle; Markus Moehler Journal: Clin Cancer Res Date: 2005-03-01 Impact factor: 12.531
Authors: Sophie Kirshberg; Uzi Izhar; Gail Amir; Jonathan Demma; Fiona Vernea; Katia Beider; Zippora Shlomai; Hanna Wald; Gideon Zamir; Oz M Shapira; Amnon Peled; Ori Wald Journal: PLoS One Date: 2011-09-15 Impact factor: 3.240
Authors: Eric Schafer; Rafael Irizarry; Sandeep Negi; Emily McIntyre; Donald Small; Maria E Figueroa; Ari Melnick; Patrick Brown Journal: Blood Date: 2010-03-09 Impact factor: 22.113
Authors: Claudia Rubie; Vilma Oliveira Frick; Pirus Ghadjar; Mathias Wagner; Henner Grimm; Benjamin Vicinus; Christoph Justinger; Stefan Graeber; Martin K Schilling Journal: J Transl Med Date: 2010-05-10 Impact factor: 5.531
Authors: Katia Beider; Michal Abraham; Michal Begin; Hanna Wald; Ido D Weiss; Ori Wald; Eli Pikarsky; Rinat Abramovitch; Evelyne Zeira; Eithan Galun; Arnon Nagler; Amnon Peled Journal: PLoS One Date: 2009-04-02 Impact factor: 3.240